Literature DB >> 25979440

Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock.

Hunter B Moore1, Ernest E Moore2, Peter J Lawson3, Eduardo Gonzalez2, Miguel Fragoso3, Alex P Morton2, Fabia Gamboni4, Michael P Chapman3, Angela Sauaia4, Anirban Banerjee4, Christopher C Silliman5.   

Abstract

INTRODUCTION: Systemic hyperfibrinolysis (accelerated clot degradation) and fibrinolysis shutdown (impaired clot degradation) are associated with increased mortality compared with physiologic fibrinolysis after trauma. Animal models have not reproduced these changes. We hypothesize rodents have a shutdown phenotype that require an exogenous profibrinolytic to differentiate mechanisms that promote or inhibit fibrinolysis.
METHODS: Fibrinolysis resistance was assessed by thrombelastography (TEG) using exogenous tissue plasminogen activator (tPA) titrations in whole blood. There were 3 experimental groups: (1) tissue injury (laparotomy/bowel crush), (2) shock (hemorrhage to mean arterial pressure of 20 mmHg), and (3) control (arterial cannulation and tracheostomy). Baseline and 30-minute postintervention blood samples were collected, and assayed with TEG challenged with taurocholic acid (TUCA).
RESULTS: Rats were resistant to exogenous tPA; the percent clot remaining 30 minutes after maximum amplitude (CL30) at 150 ng/mL (P = .511) and 300 ng/mL (P = .931) was similar to baseline, whereas 600 ng/mL (P = .046) provoked fibrinolysis. Using the TUCA challenge, the percent change in CL30 from baseline was increased in tissue injury compared with control (P = .048.), whereas CL30 decreased in shock versus control (P = .048). tPA increased in the shock group compared with tissue injury (P = .009) and control (P = .012).
CONCLUSION: Rats have an innate fibrinolysis shutdown phenotype. The TEG TUCA challenge is capable of differentiating changes in clot stability with rats undergoing different procedures. Tissue injury inhibits fibrinolysis, whereas shock promotes tPA-mediated fibrinolysis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979440      PMCID: PMC4492895          DOI: 10.1016/j.surg.2015.04.008

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  25 in total

1.  Reproducibility of an animal model simulating complex combat-related injury in a multiple-institution format.

Authors:  S David Cho; John B Holcomb; Brandon H Tieu; Michael S Englehart; Melanie S Morris; Z Ayhan Karahan; Samantha A Underwood; Patrick J Muller; M Dale Prince; Leticia Medina; Jill Sondeen; Christian Shults; Michael Duggan; Malek Tabbara; Hasan B Alam; Martin A Schreiber
Journal:  Shock       Date:  2009-01       Impact factor: 3.454

2.  Minding the gaps--and the junctions, too.

Authors:  Lawrence F Brass; Timothy J Stalker
Journal:  Circulation       Date:  2012-04-23       Impact factor: 29.690

3.  Acute coagulopathy of trauma in the rat.

Authors:  Daniel N Darlington; Teresa Craig; Mary D Gonzales; Martin G Schwacha; Andrew P Cap; Michael A Dubick
Journal:  Shock       Date:  2013-05       Impact factor: 3.454

4.  Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?

Authors:  Karim Brohi; Mitchell J Cohen; Michael T Ganter; Michael A Matthay; Robert C Mackersie; Jean-François Pittet
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

5.  Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Michael P Chapman; Theresa L Chin; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2014-12       Impact factor: 3.313

6.  A principal component analysis of coagulation after trauma.

Authors:  Matthew E Kutcher; Adam R Ferguson; Mitchell J Cohen
Journal:  J Trauma Acute Care Surg       Date:  2013-05       Impact factor: 3.313

7.  Advanced Trauma Life Support (ATLS): past, present, future--16th Stone Lecture, American Trauma Society.

Authors:  P E Collicott
Journal:  J Trauma       Date:  1992-11

8.  Hyperfibrinolysis is common in out-of-hospital cardiac arrest: results from a prospective observational thromboelastometry study.

Authors:  H Schöchl; J Cadamuro; S Seidl; A Franz; C Solomon; C J Schlimp; B Ziegler
Journal:  Resuscitation       Date:  2012-08-23       Impact factor: 5.262

9.  Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.

Authors:  Karim Brohi; Mitchell J Cohen; Michael T Ganter; Marcus J Schultz; Marcel Levi; Robert C Mackersie; Jean-François Pittet
Journal:  J Trauma       Date:  2008-05

10.  Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants.

Authors:  Elizabeth A Boonstra; Jelle Adelmeijer; Henkjan J Verkade; Marieke T de Boer; Robert J Porte; Ton Lisman
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

View more
  26 in total

1.  [Uncritical use of tranexamic acid in trauma patients : Do no further harm!]

Authors:  M Maegele
Journal:  Unfallchirurg       Date:  2016-11       Impact factor: 1.000

Review 2.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

Review 3.  Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Michael P Chapman; Kirk C Hansen; Angela Sauaia; Christopher C Silliman; Anirban Banerjee
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

4.  Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

5.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

6.  The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.

Authors:  Frederick A Moore; Ernest E Moore; Timothy R Billiar; Yoram Vodovotz; Anirban Banerjee; Lyle L Moldawer
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

7.  Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.

Authors:  Hunter B Moore; Ernest E Moore; Ioannis N Liras; Eduardo Gonzalez; John A Harvin; John B Holcomb; Angela Sauaia; Bryan A Cotton
Journal:  J Am Coll Surg       Date:  2016-01-22       Impact factor: 6.113

Review 8.  Fibrinolysis in trauma: a review.

Authors:  M J Madurska; K A Sachse; J O Jansen; T E Rasmussen; J J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2017-09-16       Impact factor: 3.693

9.  Human neutrophil elastase mediates fibrinolysis shutdown through competitive degradation of plasminogen and generation of angiostatin.

Authors:  Christopher D Barrett; Hunter B Moore; Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Michael B Yaffe
Journal:  J Trauma Acute Care Surg       Date:  2017-12       Impact factor: 3.313

10.  Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.

Authors:  H B Moore; E E Moore; M P Chapman; E Gonzalez; A L Slaughter; A P Morton; A D'Alessandro; K C Hansen; A Sauaia; A Banerjee; C C Silliman
Journal:  J Thromb Haemost       Date:  2015-09-22       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.